Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 19;12:11241–11254. doi: 10.2147/OTT.S220621

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Rao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

GATA6 knockdown partially reversed the effects of miR-27a-3p on the metastasis and angiogenesis of pancreatic carcinoma cells by regulation of VEGFA/VEGFR2 pathway. (A) Transfection of GATA6 siRNA could decrease the GATA6 protein expression in AsPC-1 and Panc-1 cells. (B) Western blotting analysis of GATA6 expression in miR-27a-3p inhibitor-treated pancreatic carcinoma cells after transfected with either GATA6 siRNA or the siRNA control. (C) GATA6 inhibition reversed the migration-suppressive effects of miR-27a-3p inhibitor on pancreatic carcinoma cells. (D) miR-27a-3p inhibitor-treated AsPC-1 and Panc-1 cells transfected with the GATA6 siRNA exhibited significantly higher tube formation capability. (E) Western blotting was performed to determine the protein expression levels of VEGFA in miR-27a-3p inhibitor-treated pancreatic carcinoma cells after transfected with GATA6 siRNA. The protein expression levels of VEGFR2 in miR-27a-3p inhibitor-treated AsPC-1 and Panc-1 cells were partially reversed upon knockdown of GATA6. *P<0.05.